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Sepsis in neonates and infants remains a major cause of death despite a decline in
child mortality and morbidity over the last decades. A key factor in further reducing poor
clinical outcomes is the optimal use of antibiotics in sepsis management. Developmental
changes such as maturation of organ function and capacity of drug metabolizing
enzymes can affect the pharmacokinetic profile and therefore the antibiotic exposure
and response in neonates and infants. Optimal antibiotic treatment of sepsis in neonates
and young infants is dependent on several key components such as the determination
of treatment phase, the administered dose and the resulted drug exposure and
microbiological response. During the initial phase of suspected sepsis, the primary focus
of empirical treatment is to assure efficacy. Once bacterial infection as the cause of sepsis
is confirmed the focus shifts toward a targeted treatment, ensuring an optimal balance
between efficacy and safety. Interpretation of antibiotic exposure and microbiological
response in neonates and infants is multifaceted. The response or treatment effect can
be determined by the microbiological parameters (MIC) together with the characteristics
of the pathogen (time- or concentration dependent). The antibiotic response is influenced
by the properties of the causative pathogen and the unique characteristics of the
vulnerable patient population such as reduced humoral response or reduced skin barrier
function. Therapeutic drug monitoring (TDM) of antibiotics may be used to increase
effectiveness while maximizing safety and minimizing the toxicity, but requires expertise
in different fields and requires collaborations between physicians, lab technicians, and
quantitative clinical pharmacologists. Understanding these clinical, pharmacological, and
microbiological components and their underlying relationship can provide a scientific
basic for proper antibiotic use and reduction of antibiotic resistance in neonates and
infants. This highlights the necessity of a close multidisciplinary collaboration between
physicians, pharmacists, clinical pharmacologists and microbiologist to assure the
optimal utilization of antibiotics in neonates and young infants.
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INTRODUCTION
Despite a decline in child mortality during the last decades, close
to 6 million children died before the age of 5 years in 2015 with
almost half of these patients dying during the neonatal period
(1). Neonates are immunologically immature, have reduced skin
barrier, reduced humoral response and a diminished microbial
diversity in gut microbiota, all contributing to a higher risk
of life-threatening bacterial infection, often presenting as sepsis
(2–5). Sepsis is defined as a clinical condition resulting from a
dysregulated immune response, triggered by an infection. The
initiation of the pro-inflammatory cascademay cause widespread
tissue injury (6–9). In 2015, infectious diseases were responsible
for 9.5% of neonatal deaths worldwide, mainly focusing on lower
and middle income countries where healthcare and appropriate
antibiotics may be difficult to access (1). It should be noted that
sepsis continues to impact not only neonates, but also affects
a considerable proportion of young and older infants receiving
intensive care. A recent study showed that global prevalence of
severe sepsis in pediatric intensive care units is 8.2% (10).
The diagnosis of sepsis in neonates and infants is complex,
and a complete discussion on clinical decision-making about
initiations of antibiotics is beyond the scope of this review
(11). Early antibiotic therapy for potential bacterial infection
in sepsis is critical with antibiotics generally being started
empirically, meaning before microbiological results are available.
Antibiotic treatment is often started before sepsis is confirmed by
microbiological diagnostics because of the lack of sensitive blood
cultures together with the insufficient predictive performance of
these analytics and as well as the possibility of sampling from the
infection site. In settings with restricted availability of standard
diagnostic tools or a high level of prior antibiotic exposure, for
example because of availability of antibiotics over the counter, a
definitive diagnosis may not be reached (12).
Neonatal sepsis can be divided into early and late onset
neonatal sepsis (EONS and LONS), which reflects the timing
of onset of symptoms, type and virulence of organism and
associated pathogenesis (2). First, EONS is defined by a life-
threatening infection during the 1 days of life. In developed
countries Group B Streptococcus and Escherichia coli account for
most episodes of EONS, whereas Klebsiella is the most common
organism in low and middle income countries (13, 14). Risk
factors for EONS are prematurity, premature and prolonged
rupture of membranes, intrapartum maternal fever (>38◦C)
and maternal Group B Streptococcus colonization (3, 15, 16).
As expected, neonates with a very low birth weight (VLBW,
<1,500 g) are more susceptible to an infection (16, 17). Second,
LONS is characterized by the onset of symptoms more than 72 h
after birth. Among VLBW neonates, Gram-positive organisms
are most commonly associated with LONS, although it has been
shown that the mortality rate is 2–3 times higher in neonates
with Gram-negative infections. Prolonged indwelling catheter
use and other invasive procedures are potential risk factors (16).
Third, invasive infections during infancy are mostly caused by
Streptococcus pneumoniae. Because of vaccinations, infections
caused by Haemophilus influenzae type b are less common in
developed countries compared to resource limited settings (7).
Currently, Salmonella spp. is one of the most common organisms
causing sepsis in low and middle income countries (18).
In the first 2 years of life, maturational processes affect
drug clearance and make antibiotic dosing more challenging,
compared to older infants where dosing is mainly adjusted by
body weight and renal function. Most of the current dosing
guidelines for antibiotic treatment are simply extrapolated
from adult studies and it has been reported that dosing
recommendations across intensive care units and international
guidelines are highly variable and inconsistent (19). We review
and discuss key components and their underlying relationships
relevant to antibiotic dose optimization in neonates and infants
with suspected or confirmed sepsis (Figure 1).
OPTIMIZATION OF ANTIBIOTIC THERAPY
IN SEPSIS: EMPIRICAL VS. TARGETED
TREATMENT
In a clinical setting, there is generally no time to wait for the
result frommicrobiologic samples when there is suspected sepsis.
Antibiotic treatment can therefore be viewed as having two
phases, namely an initial, empirical treatment phase followed by a
targeted treatment phase once a causative pathogen is confirmed
(Figure 2). Both phases are time-related, and antibiotic dose
optimization may focus on either efficacy or safety, respectively.
Empirical Treatment Phase
In the 1 hours to days of treatment, the primary focus is to
deliver effective treatment. During this earliest stage mortality
is directly related to the effects of the life-threatening infection
and managing toxicity is less central. As the causative organism
generally remains unknown, selection of the antibiotic regimen
needs to take into account the overall epidemiology of sepsis in
the age group of the patient (19).
A key parameter describing susceptibility to antibiotics and
used in dose-finding is the minimal inhibitory concentration, or
MIC, which reflects the lowest antibiotic concentration needed
to inhibit visible growth of the pathogen (20). MIC breakpoints
for pathogens are established based on various in vitro tests and
are applied to an entire population. Initial antibiotic doses should
be targeting the “worst-case” minimal inhibitory concentrations,
captured by the phrase “go hard and go home” (21). During
the empirical treatment phase, the benefits (e.g., high probability
that causative pathogens are killed) outweigh the risks (e.g.,
development of renal toxicity) and therefore a certain trade-off
in dosing regimen to achieve relatively high exposures in relation
to non-pathogen specific MIC may be acceptable.
Targeted Treatment Phase
After an initial empirical treatment there are two possible
outcomes. Treatment may be discontinued because the clinical
picture of sepsis cannot be microbiologically confirmed and
an alternative diagnosis emerges. On the other hand, the
microbiological cause confirming the diagnosis of sepsis may
be identified. In the latter case treatment will be continued
and toxicity issues become more important. During this
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FIGURE 1 | Flowchart illustrating key components and factors influencing the concepts concerning antibiotic treatment in neonates and infants. MIC, minimal
inhibitory concentration; PK, pharmacokinetics; PD, pharmacodynamics; iv, intravenous; sc, subcutaneous; po, oral.
targeted treatment phase, antibiotic dose optimization will be
individualized to achieve an optimal efficacy-safety balance
(Figure 2). When patients experience or are at high risk of
toxicity (for example because of renal failure), three options are
available: if susceptibility testing suggests a less toxic alternative,
antibiotic treatment may be switched; depending on the exact
infection and treatment response, only a short course is necessary
and treatment may be stopped; or the antibiotic is question is
considered the optimal therapeutic choice, in which case dose
adjustments will be needed, possibly combined with therapeutic
drug monitoring (TDM).
Antibiotic Drug Monitoring
The relationship between antibiotic dose and exposure is
subject to high levels of inter- and intra-individual variability
and to achieve effective antibiotic exposure, antibiotic drug
monitoring is becoming crucial. This variability is known to
be increased in patients with life-threatening infection, when
rapid pathophysiological fluctuations even over the course of
a few hours can impact the pharmacokinetics, and therefore
the relationship between dose and antibiotic exposure. Reliable
measurements are a prerequisite for effective TDM, accordingly
turn-around times >24 h should be disregarded for critically ill
patients (22). TDM is used to personalize the dosing strategies to
ensure antimicrobial exposures which have therapeutic success
and low probabilities of toxicity and generation of antimicrobial
resistance (23). The percentage of patients with sub-therapeutic
concentrations decreased from 58 to 40% after applying TDM
for vancomycin in preterm and term neonates (24). Adequate
antibiotic drug monitoring requires expertise in different fields
and calls for the collaboration of physicians together with the lab
technicians and clinical pharmacologists.
While the above is likely to be applicable to any antibiotic
treatment, different antibiotics have different characteristics
FIGURE 2 | Conceptual visualization of impact of efficacy and toxicity during
antibiotic treatment. During the empirical phase, focus lies on an efficacious
treatment and when sepsis is confirmed (∼3 days) treatment can be
individualized and focus should shift to the safety of treatment.
which are reflected in their pharmacological behavior. Most
β-lactams have a wide therapeutic window, meaning that even
high exposure is unlikely to be associated with toxicity. In
contrast, aminoglycosides and glycopeptides have a narrow
therapeutic window and require more attention to avoid toxicity.
UNDERSTANDING DOSE, DRUG
ADMINISTRATION, EXPOSURE, AND
RESPONSE
Clinical pharmacology aims to predict both efficacy and
safety based on drug properties, population or individual
pharmacokinetic behavior (PK) and pharmacodynamic,
microbiological characteristics (PD). In order to understand
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optimal and individualized dosing of antibiotic treatment, one
should be aware of the drug related processes in the human body
and their influences on each other (Figure 3).
Dose and Drug Administration
A drug can have several formulations and can be administered
through various routes, intravenous and oral being the most
frequently used (Figure 3A). However, for early treatment of
neonatal sepsis, oral administration is not clinically relevant.
The route and method of administration can influence both
PK and PD processes, and therefore needs to be considered
when determining optimized dosing recommendations.
Aminoglycosides are mostly administered via intravenous
bolus dosage to achieve effective peak concentrations,
due to concentration dependent properties. In countries
where healthcare may be difficult to access, intramuscular
administration is often applied.
Drug Exposure
The relationship between dose and drug exposure is governed by
pharmacokinetics, defined by the kinetic processes abbreviated as
ADME, which defines the absorption, distribution, metabolism,
and excretion of a drug (Figure 3B). Due to dynamic
maturation processes neonates and infants have marked
differences compared to adults in terms of physiology affecting
the different pharmacokinetic stages (25, 26). The total body
water in infancy is decreasing over time (80–90% compared to
55–60% in adults), which influences the distribution of water
soluble drugs such as gentamicin. Drug eliminating organs such
as liver and kidney are immature at birth. During the first 2
weeks of life glomerular filtration rate increases rapidly reaching
adult values within 1–2 years (27, 28). The metabolic capacity
is determined by the ontogeny of metabolizing enzymes (a
majority of them located in liver). Generally, the rate of hepatic
metabolism is low at birth and increases over time, depending on
the type of enzyme. These processes have an impact on exposure
of antibiotics, and therefore dosing needs to be adjusted based on
demographic characteristics of an individual neonate or infant.
Microbiological Response
Pharmacodynamic (PD) andmicrobiological aspects focus on the
effects of a given drug on the pathogen and body (Figure 3C). In
FIGURE 3 | General overview illustrating pharmacological key components. (A) Dose: drug properties and administration routes. (B) Exposure: Pharmacokinetic
processes and parameters, A, Absorption (e.g., intestines); D, Distribution (e.g., blood circulation); M, Metabolism (e.g., liver); E, Excretion (e.g., kidneys); Cmax, peak
concentration; AUC, area under the concentration-time curve. (C) Response: Pharmacodynamics, targets and pathogens, MIC, minimal inhibitory concentration;
T > MIC, time above MIC.
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order to elicit an effect, antibiotics need to reach certain exposure
levels to kill causative pathogens of a sepsis. The exposure
induced by the antibiotic dose will cause a response, but the main
target being the pathogen. Currently, the MIC-based approach is
most frequently applied to link drug exposure to microbiological
response (Figure 3C).
Understanding the PK of antibiotics is necessary but not
sufficient for optimizing and individualizing dosing strategies. It
is essential to also understand characteristics and dynamics of
the target (pathogen) as well (29). The growth of the pathogen
needs to be inhibited or, even better, stopped entirely by the
antibiotic agent depending on the MIC (Table 1). However the
MIC may not be a fixed value, but rather changes over time,
for example in the context of antibacterial resistance, and is also
subject to measurement errors to the test system (variations in
pH, incubation time, etc.) (38).
An increase in MICs, which is the result of decreasing
susceptibility of a pathogen in a population, must in many
cases be accompanied by dose adjustments to ensure effective
exposure and maximize the effect. Recent changes to the
interpretation of the so-called intermediate breakpoint as
representing susceptibility for which successful treatment
outcomes are likely with adjustments of the dosing regimen
reflect this (10).
UNDERSTANDING THE LINK BETWEEN
ANTIBIOTIC EXPOSURE AND
MICROBIOLOGICAL RESPONSE
With a limited pipeline of new antibiotics, relying on proper use
and understanding the link between antibiotic exposure (PK)
and microbiological response (pharmacodynamics, PD) is a key
issue concerning dosing optimization of the presently available
antibiotics (29).
In order to describe relationships between drug exposure
and microbiological effects, exposure-response parameters
are used. A PK/PD index is defined as the quantitative
relationship between an exposure-related parameter (e.g. plasma
concentration) and a microbiological parameter (e.g. MIC) (39).
Antibiotic classes can be characterized by different properties in
terms of PK/PD indices. The optimal target index is frequently
identified based on animal dose fractionation studies (37).
Already in the early 1950s Eagle et al. noticed the time dependent
properties of penicillin, and realized that penicillins are best
administered as continuous infusions, whereas a concentration
dependent agent is better given as an intravenous bolus to
achieve high maximum concentrations (40, 41).
Concentration Dependent Microbiological
Response
The bacterial killing rate of concentration dependent antibiotics
increases at high levels of the antibiotic; this applies to
aminoglycosides and fluoroquinolones. For aminoglycosides,
the antibacterial effect is related to the peak concentration
(Cmax/MIC). Depending on the antibiotic class, different ratios
apply (Table 1). The magnitude of the peak concentration is
often associated with the bacterial killing efficiency (go hard
and go home paradigm) (21, 40, 42). In addition, concentration
dependent antibiotics frequently exhibit a post antibiotic effect
(PAE). The PAE is defined as the suppression of bacterial growth
after the exposure of bacteria to an antibiotic (even in absence of
host defense mechanism) (43).
Shifts in MIC can lead to a situation where dosing
recommendations need to be revised to achieve optimal
treatment. For gentamicin, for example, an increase in MIC from
0.5 to 1.0 mg/L means that, in order to achieve similar efficacy
(similar ratio of Cmax/MIC), the dose should be increased from
5 to 7.5 mg/kg in neonates (19).
Time Dependent Microbiological Response
The effect of time dependent antibiotics relies on the length of
time that the antibiotic is in contact with causative pathogen.
For β-lactams the antibacterial effect is considered to be
time dependent and therefore the PK/PD index Time/MIC is
used (Figures 3B,C). This index is generally transformed to
fT>MIC; this reflects the percentage of time for which the free
fraction of drug concentration remains above the MIC (Table 1).
For β-lactams (penicillins, cephalosporins, carbapenems) it has
been proposed that dosing schedules should maintain plasma
concentrations above MIC for at least 50% of the dosing
interval, but the efficacy of β-lactams is enhanced with longer
exposure times. The post antibiotic effect is limited for β-lactams
with an exception for carbapenems (40). Continuous infusions
can potentially improve target attainment for fT>MIC, they
may, however, be impractical in many settings (44). Decreased
mortality has been associated with continuous infusion of β-
lactam antibiotics in critically ill patients with severe sepsis (45).
Other Relevant Indices for Microbiological
Response
Several studies have shown the importance of a third index,
namely AUC/MIC (21, 38). AUC reflects the area under the
concentration-time curve and represents the antibiotic exposure
over time. This parameter is often used for concentration
independent antibiotics with extended post antibiotic effects,
such as vancomycin. Bacterial regrowth is inhibited, even
when the concentration falls below MIC, but the effect is not
dependent on the peak concentration (37). Few antibiotics, such
as aminoglycosides and fluoroquinolones have been linked to
multiple classes and multiple corresponding indices, leading to
differences in dosing recommendations and guidelines.
CHALLENGES OF ANTIBIOTIC DOSE
OPTIMIZATION IN NEONATES AND
INFANTS
Currently, TDM of antibiotics is not widely used for antibiotic
dose optimization in neonates and infants suffering from life-
threatening infections. This is mainly related to practical barriers
of implementing TDM for improving treatment effectiveness,
such as the lack of rapid and reliable methods of analysis
of the antibiotic or the possibility that the pharmacologic
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TABLE 1 | Pharmacokinetic and pharmacodynamic indices for antimicrobial agents together with their target value and bactericidal characteristics.
PK/PD indices and their target values
Antimicrobial agents PK/PD index Target value for clinical
antibacterial efficacy
PK/PD properties References
Aminoglycosides
Gentamicin
Amikacin
Tobramycin
Cmax/MIC
≥8
8–10
8–12
Concentration dependent
killing (maximize drug
concentration)
(22)
(30)
(31)
β-lactams
Penicillins
Carbapenems
Cephalosporins
fT > MIC T>MIC > 40%
T>MIC > 50–60%
T>MIC > 40–50%
T>MIC > 60–70%
Time dependent killing
(maximize exposure time)
(32)
(33)
(33)
(33)
Glycopeptides
Vancomycin
Quinolones
Levofloxacin
Ciprofloxacin
Fluoroquinolones
AUC24/MIC
AUC/MIC
AUC/MIC
AUC24/MIC
400
100
125
100–125 (Gram-negatives)
25–35 (Gram-positives)
Time and concentration
dependent killing (maximize
daily amount of dose)
(34)
(35)
(36)
(37)
Cmax: maximum antibacterial concentration, MIC: minimal inhibitory concentration, AUC: area under the concentration-time-curve, AUC24: area under the concentration time curve
over 24 hours, fT > MIC: percentage of time for which the free fraction of drug remains above MIC.
effect is not readily measurable (due to interactions with other
drugs) (46) Beta-lactam antibiotics in particular would benefit
from dose adaptations based on measured levels, as these
are often the backbone of empiric treatment (47). Technical
bottlenecks include long turn-around times for samples, lack
of commercial assays and challenging pre-analytics, and in
the pediatric population the need for relatively large samples
volumes (Table 2). The required sampling volume, relative to
the circulating blood volume is a crucial barrier, especially in
preterm infants whose blood volume is limited. Furthermore,
concentration measurements are often collected from plasma
since these are relatively easy to obtain, although these levels
appear to be a poor descriptor of the activities of the drug at site
of action in individual patients.
Moreover, although the MIC-based approach is well-
established as a measure of the potency of an antibiotic drug,
it is determined in an in vitro setting, where the conditions
are dissimilar from those at the site of infection in the in
vivo situation. Better understanding of population-specific MICs
is demanded to guide empiric antibiotic treatment (40, 48).
Additionally, antibacterial activity is a dynamic process and since
MIC is a one-point threshold value, the MIC can only provide an
approximation on the antibacterial effect (38).
The key issue in optimizing antibiotic exposure in critically ill
patients is to respond to expectedly variable PK in patients with
life-threatening illness and at risk of infection caused by bacteria
with potentially problematic antibiotic resistance. Critical illness
leads to time-variation in multiple factors, potentially requiring
frequent dose adjustments in the most vulnerable patients rather
than simple a priori dose stratification. More knowledge is
required concerning tissue penetration of antibiotics in critically
ill neonates and infants (49). Furthermore, drug dosing is
currently being adjusted for patients with impaired kidney
function (risk for toxicity), whereas for patients with augmented
renal clearance (elevated drug clearance) no dose adjustments are
being recommended (50). Although the underlying physiological
TABLE 2 | Challenges to overcome the burden of sepsis and the opportunities to
improve diagnostic tools, measurement techniques and implementation of
modeling and simulation techniques.
Challenges; what is missing? Opportunities
• Uniform sepsis definitions for all age
groups across the pediatric age range
• Identify of biomarkers (e.g.,
presepsin or cystatin C) with
accurate thresholds
• Diagnostic tools to identify pathogens
and infection
• Use microdialysis to measure drug
concentrations at target site
• Adequate descriptors of drug
concentration at target site
• Implement therapeutic antibiotic
monitoring, especially in patients
with life-threatening infections
• Understanding PK/PD relationships and
parameters which can characterize the
dynamic process of antibacterial activity
• Apply kill-curves approach to
describe changing antibacterial
activity
• Reliable measurements for GFR in the
pediatric population (augmented renal
clearance)
• Multidisciplinary collaboration and
communication between research
groups and physicians
• Straightforward applications of
model-based approaches
• Implement modeling and simulation
strategies in clinical settings (e.g.,
for individual dose optimization)
• Implementation of adjusted dosing
guidelines in clinical practice
• Develop understandable
time-saving software tools for
individualized dosing
mechanisms of augmented renal clearance are not yet fully
understood, augmented renal clearance has not only been
observed in critically ill adults, but also in pediatric patients (50,
51). Consequently, there is a real need for reliable assessment and
monitoring of kidney function in neonates and infants. Serum
creatinine values are still widely used, although the accuracy and
usefulness of this biomarker can be questioned in neonates as
various parts of kidneys are maturing at different rates (52).
The application of pharmacometric modeling and simulation
will be needed to truly support antibiotic dosing optimization
based on the knowledge of the dose-concentration-effect
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relationship (53). The modeling and simulation strategy is still
underutilized, although it has been shown that mechanistic
modeling such as physiological-based pharmacokinetic (PBPK)
models have good predictive value and enable extrapolation by
using information about the drug and the physiology (54, 55).
Despite modeling and simulation being frequently reported in
the literature, the results and adjusted dosing recommendations
are not yet implemented in daily clinical practice (56). Dose
adjustment and individualization of antibiotics is crucial. For
instance, administration of an inefficacious (too low) dose
of antibiotics in patients with increased drug clearance can
have a negative impact on patient outcome and antibiotic
resistance.
OPPORTUNITIES: HOW TO CLOSE
KNOWLEDGE GAPS
The search for a quantitative, scientific rationale to further
enhance dosing regimens and drug combinations can benefit
tremendously from modeling and simulation strategies when
there is on-going communication and exchange between research
groups and clinicians (Table 2) (57). In order to apply these
quantitative methods directly in clinical practice, it is essential
to communicate the strengths and applicability of the model
to the users (mostly physicians). User-friendly decision support
tools, which provide quantitative, scientific output without
requiring additional time-consuming activities during routine
clinical practice, would be valuable (54, 56). An example of
these software tools is the model-supported TDM tool for
precision dosing TDMx (http://www.tdmx.eu/). Since there are
several population PKmodels published for antimicrobial agents,
researchers should assess new data or use existing data to
extend and improve existing population PK models (56, 58).
Pharmacometric PK/PD models can help identify the optimal
(effective and safe) therapeutic window necessary to successfully
treat an infection (59).
In contrast to the MIC, which reflects the susceptibility of a
pathogen at only one time point, bacterial kill-curves can offer
more detailed information about the killing activity as a function
over time and might even be used to identify the presence of
resistant subpopulations (60, 61). Bacterial kill-curves are very
labor intensive and until the method is automated and widely
implementable, this approach might not be practical (61).
Furthermore, in recent decades novel non-invasive techniques
have provided information about the process of target site
distribution. Microdialysis provides direct measurement of
concentrations of unbound antibiotics at the site of action when
the site of infection is not the bloodstream (40, 62). Measurement
of the free (unbound) drug concentration in the interstitial fluid
is better correlated with the antimicrobial efficacy, compared to
concentration measurements in plasma. Microdialysis offers a
useful sampling tool which can quantify the unbound antibiotic
at infection sites (29). Other non-invasive techniques such as
dried blood spot analysis or TDM from sweat are considered as
innovative and promising methods to tackle the known barriers
(30, 31, 34).
CONCLUSIONS
There are still numerous challenges to overcome the
burden of sepsis in neonates and infants, of which the
lack of implementation of optimized, individualized dosing
recommendations can be considered as remarkably important.
Key components for optimal antibiotic treatment of sepsis in
neonates and infants are indicated as treatment phase, dose,
drug exposure and microbiological response. During the first
days of treatment the focus lies on establishing an effective dose,
thereafter the balance is shifting toward ensuring a safe and
effective treatment. In neonates and young infants, drug exposure
is affected by developmental changes such as maturation of
organ function and metabolizing enzymes, which requires
dosing adjustments. The response or treatment effect can be
determined by the microbiological parameters (MIC) together
with the pathogen characteristics (time- or concentration
dependent). Understanding these clinical, pharmacological and
microbiological components and their underlying relationship
might provide a basis for proper antibiotic use and reduction
of antibiotic resistance. This also illustrates the necessity of
a close multidisciplinary collaboration between physicians,
pharmacists, pharmacometricians, clinical pharmacologists and
microbiologists to assure optimal utilization of antibiotics in
neonates and infants.
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